184 related articles for article (PubMed ID: 37357752)
21. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T
Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359
[TBL] [Abstract][Full Text] [Related]
22. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Bal S; Landau HJ; Shah GL; Scordo M; Dahi P; Lahoud OB; Hassoun H; Hultcrantz M; Korde N; Lendvai N; Lesokhin AM; Mailankody S; Shah UA; Smith E; Devlin SM; Avecilla S; Dogan A; Roshal M; Landgren O; Giralt SA; Chung DJ
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1394-1401. PubMed ID: 32442725
[TBL] [Abstract][Full Text] [Related]
23. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Okazuka K; Ishida T; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
Eur J Haematol; 2020 Feb; 104(2):110-115. PubMed ID: 31733155
[TBL] [Abstract][Full Text] [Related]
25. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
Shen LJ; Zhuansun SY; Ni BW; Zhang MY; Lu SS; Hua YN; Xiao D; Huang HH; Han XF; Zhong L; Zhong H; Wang T; Hou J
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2861-2867. PubMed ID: 36153871
[No Abstract] [Full Text] [Related]
26. Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.
Thurlapati A; Roubal K; Davis JA; Shah SZ; Smith D; McGann M; Gaffney K; Cendagorta A; Maldonado A; Weeda E; Hashmi H
Transplant Cell Ther; 2023 May; 29(5):340.e1-340.e4. PubMed ID: 36804934
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
30. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Mark T; Stern J; Furst JR; Jayabalan D; Zafar F; LaRow A; Pearse RN; Harpel J; Shore T; Schuster MW; Leonard JP; Christos PJ; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2008 Jul; 14(7):795-8. PubMed ID: 18541199
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
32. Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells.
Ohno S; Hayashi K; Shimizu R; Ishii A; Tanaka H
J Clin Exp Hematop; 2022 Sep; 62(3):147-153. PubMed ID: 35979578
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
35. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Kaiser MF; Hall A; Walker K; Sherborne A; De Tute RM; Newnham N; Roberts S; Ingleson E; Bowles K; Garg M; Lokare A; Messiou C; Houlston RS; Jackson G; Cook G; Pratt G; Owen RG; Drayson MT; Brown SR; Jenner MW
J Clin Oncol; 2023 Aug; 41(23):3945-3955. PubMed ID: 37315268
[TBL] [Abstract][Full Text] [Related]
36. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.
Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M
Stem Cell Res Ther; 2015 Apr; 6(1):64. PubMed ID: 25889496
[TBL] [Abstract][Full Text] [Related]
37. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
[TBL] [Abstract][Full Text] [Related]
38. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Gastineau DA; Litzow MR; Fonseca R; Roy V; Rajkumar SV; Gertz MA
Leukemia; 2007 Sep; 21(9):2035-42. PubMed ID: 17581613
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
Xu JY; Yan WW; Fan HS; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2338-2344. PubMed ID: 35970791
[No Abstract] [Full Text] [Related]
40. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]